BRCA1/2 germline mutations are the strongest known genetic risk factors for epithelial ovarian cancer and are found in 6–16% of patients [5, 6], and treatment with poly (ADP-ribose) polymerase inhibitors (PARPi) has a significant response based on “synergistic lethal effects” [7] . Here, BRCA1 is linked to ovarian carcinoma.